{"entity":{"id":"nct07667868","kind":"trial","name":"A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1 trial of BP2202 run by BrightPath Biotherapeutics Co., Ltd., not yet recruiting.","summary":"A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT07667868 by BrightPath Biotherapeutics Co., Ltd., with 18 participants planned, started 2026-10-01. Conditions recorded: Relapsed/Refractory Multiple Myeloma (RRMM). Interventions recorded: BP2202.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07667868","url":"https://clinicaltrials.gov/study/NCT07667868"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["myeloma-relapsed-refractory"],"sections":[],"technologies":[],"targets":[],"drugs":["bp2202"],"companies":["brightpath-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07667868","phase":"1","setting":"A Phase I, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma","sponsor":"BrightPath Biotherapeutics Co., Ltd.","enrolled":18,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07667868/","neighbours":{"cancer":[{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"drug":[{"id":"bp2202","kind":"drug","name":"BP2202","route":"/drugs/bp2202/"}],"company":[{"id":"brightpath-biotherapeutics","kind":"company","name":"BrightPath Biotherapeutics","route":"/companies/brightpath-biotherapeutics/"}]}}